

Match Overview

1	Internet 74 words www.ncbi.nlm.nih.gov	5%
2	Crossref 63 words Jamie A. Saxon, Lynette M. Sholl, Pasi A. Jänne. "EGFR... L858M/L861Q cis Mutations Confer Selective Sensitivity t	4%
3	Crossref 54 words Yangyang Cai, Xu Wang, Ye Guo, Chao Sun, Yinghui Xu, Shi Qiu, Kewei Ma. "Successful treatment of a lung ade ...	4%
4	Internet 44 words crawled on 14-May-2020 bmccancer.biomedcentral.com	3%
5	Internet 43 words crawled on 01-May-2020 wcllc2018.iaslc.org	3%
6	Internet 34 words crawled on 22-Jul-2019 journals.sagepub.com	2%
7	Crossref 33 words "INVITED ABSTRACTS", Journal of Thoracic Oncology, 2 013	2%
8	Internet 18 words crawled on 30-Dec-2017 jpkc.shutcm.edu.cn	1%

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 58038

Manuscript Type: CASE REPORT

8 Efficacy of afatinib in patients with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report

He SY *et al.* EGFR rare co-mutation response to afatinib

He Shu-Yan, Lin Qing-Feng, Chen Jie, Yu Gui-Ping, Zhang Jun-Ling, Shen Dong

Abstract

BACKGROUND

2 The most common EGFR mutations are in-frame deletions in exon 19 and exon 21 mutations. **5** And EGFR-tyrosine kinase inhibitor (TKI) as the standard first line treatment shows good response to classical EGFR mutations. With the development of next generation sequence, **15** some uncommon genomic mutations are detected. However, the

ALL

IMAGES

VIDEOS

Add the Give with Bing extension

52,200 Results

Any time

The effectiveness of afatinib in patients with lung ...

<https://journals.sagepub.com/doi/pdf/10.1177/1758835920946156>

of NSCLC **patients** with **EGFR mutations** have **rare** or uncommon **mutations**, including L861Q, G719X, and S768I. ... **epidermal growth factor receptor mutation** ... tyrosine kinase inhibitor-afatinib in lung **adenocarcinoma patients**. Oncotarget 2016; 7: 12404–12413.

The effectiveness of afatinib in patients with lung ...

<https://journals.sagepub.com/doi/full/10.1177/1758835920946156>

In contrast, the first-generation **EGFR** TKIs gefitinib and erlotinib have shown inconsistent responses in **patients** with uncommon **EGFR mutations**. 32–35 In in vitro studies, **afatinib** had a lower half-maximal inhibitory concentration (IC 50) in Ba/F3 cell lines transfected with S768I or G719X **mutations** than first-generation **EGFR** TKIs. 36,37 **Afatinib** also had a lower IC 50 in Ba/F3 cells transfected with the complex **EGFR mutations** ...

Author: Shang-Gin Wu, Chong-Jen Yu, James C... Publish Year: 2020

Response to Afatinib in a Patient with Non-Small Cell Lung ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913761>

This is the first **case report** describing a NSCLC **patient** harboring a **rare** HER2 R896G **mutation** who responds to **afatinib**. This **case** suggests that **afatinib** might be efficacious in NSCLC **patients** harboring HER2 R896G **mutations**, and these results need to be further studied in prospective clinical trials.

Author: Ling Lin, Hongfei Ge, Zhengqing Yan, G... Publish Year: 2019

Efficacy of afatinib treatment for lung adenocarcinoma ...

<https://www.researchgate.net/publication/333756450...>

Exon 18 delE709_T710insD is an extremely **rare mutation** in **epidermal growth factor receptor (EGFR)** in non-small-cell **lung cancer** (NSCLC); the **efficacy** of **EGFR** tyrosine kinase inhibitors against ...

Effectiveness of afatinib in lung cancer with paralytic ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/rcr2.197>

Possible explanation of **afatinib efficacy** in our **patient** is its activity against the uncommon S768I **mutation** in **EGFR**. The combined post hoc analysis of LUX-Lung 2, 3, and 6 indicated that **afatinib** was effective in **patients** with certain uncommon **EGFR mutations**, especially G719X, L861G, and S768I 2. However, **afatinib** can cause serious side effects such as diarrhoea.

Cited by: 3 Author: Haruki Kobayashi, Kazushige Wakuda, Tos... Publish Year: 2016

Case report: Durable response to afatinib in a patient ...

<https://www.sciencedirect.com/science/article/pii/S0169500216304640>

Nov 01, 2016 · We **report a case** of NSCLC with **EGFR mutations** G719C, S768I and KRAS E49 K **mutation**. • Treatment with **afatinib** resulted in a decrease of the **patient's** serum CEA level. • **Afatinib** was clinically effective for this **patient** as confirmed by PET-CT. • **Efficacy of afatinib** for **EGFR**(S768I) was observed by in vitro assay as well.

The effectiveness of afatinib and osimertinib in a Chinese ...

europepmc.org/articles/PMC6091473

Aug 10, 2018 · We showed the clinical **efficacy of afatinib** and osimertinib in a **patient** with NSCLC positive uncommon triple **EGFR mutations**. This **case** had several unusual features: three **rare EGFR mutations** (L833V, H835L, and R670W) were present in the same **patient**; the first **case** study of the R670W **mutation**; T790M was a secondary resistant mechanism in NSCLC **patient** harboring L833V, H835L, and R670W treated with **afatinib**; and **patient** ...

Afatinib for the Treatment of NSCLC Harboring Uncommon ...

<https://www.sciencedirect.com/science/article/pii/S1556086420300149>

May 01, 2020 · Introduction. Limited clinical data are available regarding the **efficacy** of **EGFR** tyrosine kinase inhibitors (**EGFR** TKIs) in **patients** with NSCLC harboring uncommon **EGFR mutations**. This pooled analysis assessed the activity of **afatinib** in 693 **patients** with tumors harboring uncommon **EGFR mutations** treated in randomized clinical trials, compassionate-use and expanded-access programs, ...

Emergence of EGFR G724S mutation in EGFR-mutant lung ...

<https://www.researchgate.net/publication/318303305...>

26 In another **case report** of **lung adenocarcinoma**, even though **EGFR** G724S was detected before osimertinib treatment, G724S clone significantly increased after osimertinib resistance, which further ...

Current Two EGFR Mutations in Lung Adenocarcinoma – Case ...

<https://www.researchgate.net/publication/275050861...>

There are many complex and **rare mutations** in the **epidermal growth factor receptor (EGFR)** gene in non-small cell **lung cancer** (NSCLC) other than the two classical **mutations** of L858R and exon 19 ...

Some results are removed in response to a notice of local law requirement. For more information, please see [here](#).

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

53,300 Results

Any time ▾

[The effectiveness of afatinib in patients with lung ...](#)

<https://journals.sagepub.com/doi/pdf/10.1177/1758835920946156> ▾

of NSCLC **patients** with **EGFR mutations** have **rare** or uncommon **mutations**, including L861Q, G719X, and S768I. ... **epidermal growth factor receptor mutation** ... tyrosine kinase inhibitor-**afatinib** in lung **adenocarcinoma patients**. Oncotarget 2016; 7: 12404–12413.

[Efficacy of afatinib treatment for lung adenocarcinoma ...](#)

<https://www.researchgate.net/publication/333756450...>

Exon 18 delE709_T710insD is an extremely **rare mutation** in **epidermal growth factor receptor** (EGFR) in non-small-cell **lung** cancer (NSCLC); the **efficacy** of **EGFR** tyrosine kinase inhibitors against ...

[The effectiveness of afatinib in patients with lung ...](#)

<https://journals.sagepub.com/doi/full/10.1177/1758835920946156>

This study was conducted in the National Taiwan University Hospital (NTUH) from June 2005 to March 2020. We enrolled **patients** if they had (1) a stage IV disease status or stage I–III **lung adenocarcinoma** with a subsequent systemic relapse, (2) tumors with complex **EGFR mutations**, and (3) first-line systemic treatment with first-generation (gefitinib or erlotinib) or second-generation (**afatinib** ...

Author: Shang-Gin Wu, Chong-Jen Yu, James C... **Publish Year:** 2020

[Effectiveness of afatinib in lung cancer with paralytic ...](#)

<https://onlinelibrary.wiley.com/doi/full/10.1002/rcr2.197>

Introduction. **Epidermal growth factor receptor** (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and **afatinib**, are currently considered standard therapy regimens for non-small cell **lung** cancer (NSCLC) harbouring **EGFR mutations** due to high response rate and prolonged progression-free survival (PFS) observed in several randomized clinical trials (RCTs).

Cited by: 3 **Author:** Haruki Kobayashi, Kazushige Wakuda, Tos...

Publish Year: 2016